Article

CMS designates aspheric lens as NTIOL

Baltimore-The Centers for Medicare and Medicaid Services (CMS) has designated a three-piece, aspheric, foldable IOL (Affinity Collamer Model CQ2015A, STAAR Surgical Co.) as a new technology IOL (NTIOL), according to the company.

Baltimore-The Centers for Medicare and Medicaid Services (CMS) has designated a three-piece, aspheric, foldable IOL (Affinity Collamer Model CQ2015A, STAAR Surgical Co.) as a new technology IOL (NTIOL), according to the company.

“This is the first step in our plans to refresh our entire U.S. cataract product offerings,” said Barry G. Caldwell, president and chief executive officer, STAAR Surgical.

The approval for NTIOL reimbursement status means that Medicare will provide an additional reimbursement of $50 per lens when the lens is implanted in a Medicare patient in an ambulatory surgical center. The NTIOL subset for reduced spherical aberrations, to which this lens has been approved, allows for the additional reimbursement from March 17, 2008, until Feb. 26, 2011.

To receive NTIOL designation, an IOL first must be approved by the FDA, with labeling and advertising consistent with the specific claim or characteristic for which CMS approval is being sought. In addition, evidence must exist that the use of the IOL results in measurable, clinically meaningful, improved patient outcomes in comparison with use of currently available lenses.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.